Vivani Medical (NASDAQ:VANI) Director Purchases $1,685,497.17 in Stock

Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams bought 1,575,231 shares of the company’s stock in a transaction that occurred on Sunday, March 15th. The stock was purchased at an average cost of $1.07 per share, with a total value of $1,685,497.17. Following the acquisition, the director directly owned 31,357,183 shares in the company, valued at $33,552,185.81. This trade represents a 5.29% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Gregg Williams also recently made the following trade(s):

• On Tuesday, January 27th, Gregg Williams purchased 1,351,351 shares of Vivani Medical stock. The stock was acquired at an average price of $1.48 per share, with a total value of $1,999,999.48.
• On Thursday, January 15th, Gregg Williams purchased 1,737,765 shares of Vivani Medical stock. The shares were acquired at an average cost of $1.14 per share, for a total transaction of $1,981,052.10.

Vivani Medical Stock Down 3.3%

Shares of Vivani Medical stock opened at $1.17 on Thursday. The company has a market capitalization of $91.46 million, a price-to-earnings ratio of -2.60 and a beta of 3.17. The stock’s 50-day simple moving average is $1.28 and its 200-day simple moving average is $1.36. Vivani Medical, Inc. has a 52 week low of $0.91 and a 52 week high of $1.92.

Hedge Funds Weigh In On Vivani Medical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VANI. Panagora Asset Management Inc. purchased a new position in Vivani Medical during the 2nd quarter valued at approximately $25,000. Citadel Advisors LLC purchased a new stake in shares of Vivani Medical during the 3rd quarter worth approximately $26,000. Susquehanna International Group LLP boosted its position in shares of Vivani Medical by 100.5% during the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock valued at $46,000 after acquiring an additional 16,200 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Vivani Medical during the 4th quarter valued at approximately $60,000. Finally, Renaissance Technologies LLC grew its holdings in shares of Vivani Medical by 118.4% in the fourth quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock valued at $121,000 after purchasing an additional 53,127 shares in the last quarter. 6.78% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

VANI has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Vivani Medical in a research note on Friday, January 9th. Wall Street Zen upgraded shares of Vivani Medical to a “sell” rating in a research report on Saturday, November 22nd. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $4.00.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.